The endocytosis and intracellular fate of nanomedicines: Implication for rational design

Asian Journal of Pharmaceutical Sciences

Volumn 8, Issue 1, 2013, Pages 1-10

  Kou, Longfa ^a   Sun, Jin ^a   Zhai, Yinglei ^a   He, Zhonggui ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Caveolae; Clathrin; Endocytosis; Intracellular fate; Nanomedicines; Organelle target; Transcytosis

Indexed keywords

ADENOSINE TRIPHOSPHATASE INHIBITOR; AMILORIDE; CAVEOLIN; CAVEOLIN 1; CLATHRIN; CYTOCHALASIN D; GUANOSINE TRIPHOSPHATASE; IMMUNOGLOBULIN; LOW DENSITY LIPOPROTEIN; MACROGOL; NANOPARTICLE; OPSONIN; POLYMER; PROTEIN TYROSINE KINASE; ROTTLERIN; SHIGA TOXIN; TRANSFERRIN; TRANSFERRIN RECEPTOR; VINYL DERIVATIVE;

ACIDIFICATION; ARTICLE; CAVEOLA; CELL DENSITY; CELL FATE; CELL MIGRATION; CELL ORGANELLE; COATED VESICLE; CONFOCAL MICROSCOPE; CYTOTOXICITY; DEGRADATION; DRUG DELIVERY SYSTEM; DRUG MECHANISM; DRUG TARGETING; ENDOCYTOSIS; ENDOPLASMIC RETICULUM; ENDOSOME; HYDROPHOBICITY; LYSOSOME; MACROPHAGE; MITOCHONDRIAL TARGETING SIGNAL; MULTIVESICULAR BODY; NANOMEDICINE; NUCLEAR LOCALIZATION SIGNAL; PARTICLE SIZE; PHAGOCYTOSIS; PHAGOSOME; PINOCYTOSIS; STATIC ELECTRICITY; SURFACE CHARGE; TECHNOLOGY; TRANSCYTOSIS;

EID: 84881351706     PISSN: 18180876     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajps.2013.07.001     Document Type: Article

References (98)

1. Moghimi SM, Hunter AC, Murray JC. Nanomedicine: current status and future prospects. FASEB J. 2005, 19: 311-330.
2. Sumer B, Gao J. Theranostic nanomedicine for cancer. Nanomedicine. 2008, 3: 137-140.
3. Wang J, Byrne JD, Napier ME, et al. More effective nanomedicines through particle design. Small. 2011, 7: 1919-1931.
4. Rappoport J. Focusing on clathrin-mediated endocytosis. Biochem J. 2008, 412: 415-423.
5. Aderem A, Underhill DM. Mechanisms of phagocytosis in macrophages. Annu Rev Immunol. 1999, 17: 593-623.
6. Xiang S, Tong H, Shi Q, et al. Uptake mechanisms of non-viral gene delivery. J Controlled Release. 2012, 158: 371-378.
7. Pucadyil TJ, Schmid SL. Conserved functions of membrane active GTPases in coated vesicle formation. Science. 2009, 325: 1217-1220.
8. Doherty GJ, McMahon HT. Mechanisms of endocytosis. Annu Rev Biochem. 2009, 78: 857-902.
9. Benmerah A, Lamaze C. Clathrin-Coated Pits: Vive La Différence? Traffic. 2007, 8: 970-982.
10. Delva E, Jennings JM, Calkins CC, et al. Pemphigus vulgaris IgG-induced desmoglein-3 endocytosis and desmosomal disassembly are mediated by a clathrin-and dynamin-independent mechanism. J Biol Chem. 2008, 283: 18303-18313.
11. Richard JP, Melikov K, Brooks H, et al. Cellular uptake of unconjugated TAT peptide involves clathrin-dependent endocytosis and heparan sulfate receptors. J Biol Chem. 2005, 280: 15300-15306.
12. Medina-Kauwe LK. "Alternative" endocytic mechanisms exploited by pathogens: New avenues for therapeutic delivery? Adv Drug Del Rev. 2007, 59: 798-809.
13. Pelkmans L, Püntener D, Helenius A. Local actin polymerization and dynamin recruitment in SV40-induced internalization of caveolae. Science. 2002, 296: 535-539.
14. Khalil IA, Kogure K, Akita H, et al. Uptake pathways and subsequent intracellular trafficking in nonviral gene delivery. Pharmacol Rev. 2006, 58: 32-45.
15. Parton RG, Simons K. The multiple faces of caveolae. Nat Rev Mol Cell Biol. 2007, 8: 185-194.
16. Kasamatsu H, Nakanishi A. How do animal DNA viruses get to the nucleus? Annu Rev Microbiol. 1998, 52: 627-686.
17. Pelkmans L, Kartenbeck J, Helenius A. Caveolar endocytosis of simian virus 40 reveals a new two-step vesicular-transport pathway to the ER. Nat Cell Biol. 2001, 3: 473-483.
18. Mercer J, Helenius A. Virus entry by macropinocytosis. Nat Cell Biol. 2009, 11: 510-520.
19. Mayor S, Pagano RE. Pathways of clathrin-independent endocytosis. Nat Rev Mol Cell Biol. 2007, 8: 603-612.
20. Gumbleton M, Stephens DJ. Coming out of the dark: the evolving role of fluorescence imaging in drug delivery research. Adv Drug Del Rev. 2005, 57: 5-15.
21. Duit S, Mayer H, Blake SM, et al. Differential functions of ApoER2 and very low density lipoprotein receptor in Reelin signaling depend on differential sorting of the receptors. J Biol Chem. 2010, 285: 4896-4908.
22. Liu AP, Aguet F, Danuser G, et al. Local clustering of transferrin receptors promotes clathrin-coated pit initiation. J Cell Biol. 2010, 191: 1381-1393.
23. Hamelers IHL, Staffhorst RWHM, Voortman J, et al. High cytotoxicity of cisplatin nanocapsules in ovarian carcinoma cells depends on uptake by caveolae-mediated endocytosis. Clin Cancer Res. 2009, 15: 1259-1268.
24. Sandvig K, Bergan J, Dyve AB, et al. Endocytosis and retrograde transport of Shiga toxin. Toxicon. 2010, 56: 1181-1185.
25. Petrescu AD, Vespa A, Huang H, et al. Fluorescent sterols monitor cell penetrating peptide Pep-1 mediated uptake and intracellular targeting of cargo protein in living cells. Biochim Biophys Acta Biomembr. 2009, 1788: 425-441.
26. Bareford LM, Swaan PW. Endocytic mechanisms for targeted drug delivery. Adv Drug Del Rev. 2007, 59: 748-758.
27. Wolf M, Deal EM, Greenberg HB. Rhesus rotavirus trafficking during entry into MA104 cells is restricted to the early endosome compartment. J Virol. 2012, 86: 4009-4013.
28. Schmerk CL, Duplantis BN, Howard PL, et al. A Francisella novicida pdpA mutant exhibits limited intracellular replication and remains associated with the lysosomal marker LAMP-1. Microbiology. 2009, 155: 1498-1504.
29. Sharma P, Ignatchenko V, Grace K, et al. Endoplasmic reticulum protein targeting of phospholamban: a common role for an N-terminal di-arginine motif in ER retention? PloS one. 2010, 5: e11496.
30. Collins TP, Bayliss R, Churchill GC, et al. NAADP influences excitation-contraction coupling by releasing calcium from lysosomes in atrial myocytes. Cell calcium. 2011, 50: 449-458.
31. Nichols B. Caveosomes and endocytosis of lipid rafts. J Cell Sci. 2003, 116: 4707-4714.
32. Vercauteren D, Vandenbroucke RE, Jones AT, et al. The use of inhibitors to study endocytic pathways of gene carriers: optimization and pitfalls. Mol Ther. 2009, 18: 561-569.
33. Hong S, Rattan R, Majoros IJ, et al. The role of ganglioside GM1 in cellular internalization mechanisms of poly (amidoamine) dendrimers. Bioconj Chem. 2009, 20: 1503-1513.
34. Ivanov AI. Pharmacological inhibition of endocytic pathways: is it specific enough to be useful? Methods Mol Biol. 2008, 440: 15-33.
35. Diken M, Kreiter S, Selmi A, et al. Selective uptake of naked vaccine RNA by dendritic cells is driven by macropinocytosis and abrogated upon DC maturation. Gene Ther. 2011, 18: 702-708.
36. Ter-Avetisyan G, Tünnemann G, Nowak D, et al. Cell entry of arginine-rich peptides is independent of endocytosis. J Biol Chem. 2009, 284: 3370-3378.
37. Zhang S, Li J, Lykotrafitis G, et al. Size-dependent endocytosis of nanoparticles. Adv Mater. 2008, 21: 419-424.
38. Huang M, Ma Z, Khor E, et al. Uptake of FITC-chitosan nanoparticles by A549 cells. Pharm Res. 2002, 19: 1488-1494.
39. Coulman SA, Anstey A, Gateley C, et al. Microneedle mediated delivery of nanoparticles into human skin. Int J Pharm. 2009, 366: 190-200.
40. Vandamme TF, Brobeck L. Poly (amidoamine) dendrimers as ophthalmic vehicles for ocular delivery of pilocarpine nitrate and tropicamide. J Controlled Release. 2005, 102: 23-38.
41. Yeung T, Gilbert GE, Shi J, et al. Membrane phosphatidylserine regulates surface charge and protein localization. Science. 2008, 319: 210-213.
42. Vina-Vilaseca A, Bender-Sigel J, Sorkina T, et al. Protein kinase C-dependent ubiquitination and clathrin-mediated endocytosis of the cationic amino acid transporter CAT-1. J Biol Chem. 2011, 286: 8697-8706.
43. Kovács T, Kárász A, Szöllosi J, et al. The density of GM1-enriched lipid rafts correlates inversely with the efficiency of transfection mediated by cationic liposomes. Cytometry A. 2009, 75: 650-657.
44. Harush-Frenkel O, Rozentur E, Benita S, et al. Surface charge of nanoparticles determines their endocytic and transcytotic pathway in polarized MDCK cells. Biomacromolecules. 2008, 9: 435-443.
45. Perumal OP, Inapagolla R, Kannan S, et al. The effect of surface functionality on cellular trafficking of dendrimers. Biomaterials. 2008, 29: 3469-3476.
46. Vighi E, Leo E. Studying the in vitro behavior of cationic solid lipid nanoparticles as a nonviral vector. Nanomedicine (Lond). 2012, 7: 9-12.
47. Qaddoumi MG, Ueda H, Yang J, et al. The characteristics and mechanisms of uptake of nanoparticles in rabbit conjunctival epithelial cell layers. Pharm Res. 2004, 21: 641-648.
48. Lankveld DP, Rayavarapu RG, Krystek P, et al. Blood clearance and tissue distribution of PEGylated and non-PEGylated gold nanorods after intravenous administration in rats. Nanomedicine. 2011, 6: 339-349.
49. Larsen EKU, Nielsen T, Wittenborn T, et al. Accumulation of magnetic iron oxide nanoparticles coated with variably sized polyethylene glycol in murine tumors. Nanoscale. 2012, 4: 2352-2361.
50. Daou TJ, Li L, Reiss P, et al. Effect of poly (ethylene glycol) length on the in vivo behavior of coated quantum dots. Langmuir. 2009, 25: 3040-3044.
51. Kaneda Y, Tsutsumi Y, Yoshioka Y, et al. The use of PVP as a polymeric carrier to improve the plasma half-life of drugs. Biomaterials. 2004, 25: 3259-3266.
52. Riche EL, Erickson BW, Cho MJ. Novel long-circulating liposomes containing peptide library-lipid conjugates: synthesis and in vivo behavior. J Drug Target. 2004, 12: 355-361.
53. Moore A, Marecos E, Bogdanov A, et al. Tumoral distribution of long-circulating dextran-coated iron oxide nanoparticles in a rodent model1. Radiology. 2000, 214: 568-574.
54. Lu Z, Qiao Y, Zheng XT, et al. Effect of particle shape on phagocytosis of CdTe quantum dot-cystine composites. Med Chem Comm. 2010, 1: 84-86.
55. Champion JA, Mitragotri S. Shape induced inhibition of phagocytosis of polymer particles. Pharm Res. 2009, 26: 244-249.
56. Gratton SEA, Ropp PA, Pohlhaus PD, et al. The effect of particle design on cellular internalization pathways. Proc Natl Acad Sci. 2008, 105: 11613-11618.
57. Mitragotri S, Lahann J. Physical approaches to biomaterial design. Nat Mater. 2009, 8: 15-23.
58. Meng H, Yang S, Li Z, et al. Aspect ratio determines the quantity of mesoporous silica nanoparticle uptake by a small GTPase-dependent macropinocytosis mechanism. ACS nano. 2011, 5: 4434-4447.
59. DeSimone J. Engineered colloids having particles of controlled size, shape, and chemistry. BAPS. 2009, 54.
60. Fujimoto T, Kogo H, Nomura R, et al. Isoforms of caveolin-1 and caveolar structure. JCell Sci. 2000, 113: 3509-3517.
61. Sahay G, Kim JO, Kabanov AV, et al. The exploitation of differential endocytic pathways in normal and tumor cells in the selective targeting of nanoparticulate chemotherapeutic agents. Biomaterials. 2010, 31: 923-933.
62. Tiruppathi C, Naqvi T, Wu Y, et al. Albumin mediates the transcytosis of myeloperoxidase by means of caveolae in endothelial cells. Proc Natl Acad Sci. 2004, 101: 7699-7704.
63. Hu G, Minshall RD. Regulation of transendothelial permeability by Src Kinase. Microvasc Res. 2009, 77: 21-25.
64. Schnitzer JE. Caveolae: from basic trafficking mechanisms to targeting transcytosis for tissue-specific drug and gene delivery in vivo. Adv Drug Del Rev. 2001, 49: 265-280.
65. Trachsel E, Neri D. Antibodies for angiogenesis inhibition, vascular targeting and endothelial cell transcytosis. Adv Drug Del Rev. 2006, 58: 735-754.
66. Bouzin C, Feron O. Targeting tumor stroma and exploiting mature tumor vasculature to improve anti-cancer drug delivery. Drug Resist Update. 2007, 10: 109-120.
67. Vogel SM, Easington CR, Minshall RD, et al. Evidence of transcellular permeability pathway in microvessels. Microvasc Res. 2001, 61: 87-101.
68. Gradishar WJ. Albumin-bound paclitaxel: a next-generation taxane. Expert Opin Pharmacother. 2006, 7: 1041-1053.
69. Des Rieux A, Fievez V, Théate I, et al. An improved in vitro model of human intestinal follicle-associated epithelium to study nanoparticle transport by M cells. Eur J Pharm Sci. 2007, 30: 380-391.
70. Kyd JM, Cripps AW. Functional differences between M cells and enterocytes in sampling luminal antigens. Vaccine. 2008, 26: 6221-6224.
71. Des Rieux A, Fievez V, Garinot M, et al. Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J Controlled Release. 2006, 116: 1-27.
72. Des Rieux A, Fievez V, Garinot M, et al. Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J Controlled Release. 2006, 116: 1-27.
73. Clark M, Jepson MA, Hirst BH. Exploiting M cells for drug and vaccine delivery. Adv Drug Del Rev. 2001, 50: 81-106.
74. Jepson MA, Clark M, Hirst BH. M cell targeting by lectins: a strategy for mucosal vaccination and drug delivery. Adv Drug Del Rev. 2004, 56: 511-525.
75. Lim JS, Na HS, Lee HC, et al. Caveolae-mediated entry of Salmonella typhimurium in a human M-cell model. Biochem Biophys Res Commun. 2009, 390: 1322-1327.
76. Green BT, Brown DR. Differential effects of clathrin and actin inhibitors on internalization of Escherichia coli and Salmonella choleraesuis in porcine jejunal Peyer's patches. Vet Microbiol. 2006, 113: 117-122.
77. Buda A, Sands C, Jepson MA. Use of fluorescence imaging to investigate the structure and function of intestinal M cells. Adv Drug Del Rev. 2005, 57: 123-134.
78. Garinot M, Fiévez V, Pourcelle V, et al. PEGylated PLGA-based nanoparticles targeting M cells for oral vaccination. J Controlled Release. 2007, 120: 195-204.
79. Kim WJ, Yockman JW, Lee M, et al. Soluble Flt-1 gene delivery using PEI-g-PEG-RGD conjugate for anti-angiogenesis. J Controlled Release. 2005, 106: 224-234.
80. Rajapaksa TE, Stover-Hamer M, Fernandez X, et al. Claudin 4-targeted protein incorporated into PLGA nanoparticles can mediate M cell targeted delivery. J Controlled Release. 2010, 142: 196-205.
81. Conner SD, Schmid SL. Regulated portals of entry into the cell. Nature. 2003, 422: 37-44.
82. Neufeld EF. Lysosomal storage diseases. Annu Rev Biochem. 1991, 60: 257-280.
83. Belchetz P, Crawley J, Braidman I, et al. Treatment of Gaucher's disease with liposome-entrapped glucocerebroside: β-glucosidase. The Lancet. 1977, 310: 116-117.
84. Chu Z, Sun Y, Kuan CY, et al. Saposin C: neuronal effect and CNS delivery by liposomes. Ann N Y Acad Sci. 2005, 1053: 237-246.
85. Guo CJ, Wu YY, Yang LS, et al. Infectious spleen and kidney necrosis virus (a fish iridovirus) enters mandarin fish fry cells via caveola-dependent endocytosis. J Virol. 2012, 86: 2621-2631.
86. Costin G-E, Trif M, Nichita N, et al. pH-sensitive liposomes are efficient carriers for endoplasmic reticulum-targeted drugs in mouse melanoma cells. Biochem Biophys Res Commun. 2002, 293: 918-923.
87. Sneh-Edri H, Likhtenshtein D, Stepensky D. Intracellular targeting of PLGA nanoparticles encapsulating antigenic peptide to the endoplasmic reticulum of dendritic cells and its effect on antigen cross-presentation in vitro. Mol Pharm. 2011, 8: 1266-1275.
88. Murthy N, Campbell J, Fausto N, et al. Bioinspired pH-responsive polymers for the intracellular delivery of biomolecular drugs. Bioconj Chem. 2003, 14: 412-419.
89. Park JY, Choi H, Hwang JS, et al. Enhanced depigmenting effects of N-glycosylation inhibitors delivered by pH-sensitive liposomes into HM3KO melanoma cells. J Cosmet Sci. 2008, 59: 139-150.
90. Wunderbaldinger P, Josephson L, Weissleder R. Tat peptide directs enhanced clearance and hepatic permeability of magnetic nanoparticles. Bioconj Chem. 2002, 13: 264-268.
91. Marty C, Meylan C, Schott H, et al. Enhanced heparan sulfate proteoglycan-mediated uptake of cell-penetrating peptide-modified liposomes. Cell Mol Life Sci. 2004, 61: 1785-1794.
92. Sethuraman VA, Bae YH. TAT peptide-based micelle system for potential active targeting of anti-cancer agents to acidic solid tumors. J Controlled Release. 2007, 118: 216-224.
93. Sahoo SK, Labhasetwar V. Enhanced antiproliferative activity of transferrin-conjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention. Mol Pharm. 2005, 2: 373-383.
94. Cheng F-Y, Wang SP-H, Su C-H, et al. Stabilizer-free poly (lactide-co-glycolide) nanoparticles for multimodal biomedical probes. Biomaterials. 2008, 29: 2104-2112.
95. Hild W, Breunig M, Göpferich A. Quantum dots-nano-sized probes for the exploration of cellular and intracellular targeting. Eur J Pharm Biopharm. 2008, 68: 153-168.
96. Rozenzhak SM, Kadakia MP, Caserta TM, et al. Cellular internalization and targeting of semiconductor quantum dots. Chem Commun. 2005: 2217-2219.
97. Jesus M, Berry CC. Tat peptide as an efficient molecule to translocate gold nanoparticles into the cell nucleus. Bioconj Chem. 2005, 16: 1176-1180.
98. Savić R, Luo L, Eisenberg A, et al. Micellar nanocontainers distribute to defined cytoplasmic organelles. Science. 2003, 300: 615-618.